Oral vinorelbine/paclitaxel combination treatment of metastatic breast cancer : a phase I study

• Published in: Cancer chemotherapy and pharmacology Vol. 59; no. 6; pp. 703 - 709
• Main Authors: DELVA, R, PIENKOWSKI, T, TUBIANA, N, VANHOEFER, U, LONGEREY, B, DOUVILLE, I
• Format: Journal Article
• Language: English
• Published: Berlin Springer 01.06.2007; Springer Nature B.V
• Subjects: Administration, Oral; Antineoplastic agents; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Breast Neoplasms - drug therapy; Breast Neoplasms - pathology; Drug Administration Schedule; Female; Gynecology. Andrology. Obstetrics; Humans; Mammary gland diseases; Maximum Tolerated Dose; Medical sciences; Neoplasm Metastasis; Neutropenia - chemically induced; Paclitaxel - administration & dosage; Paclitaxel - adverse effects; Pharmacology. Drug treatments; Salvage Therapy; Tumors; Vinblastine - administration & dosage; Vinblastine - adverse effects; Vinblastine - analogs & derivatives; Antineoplastic agent; Human; Oral vinorelbine; Oral administration; Recommended dose; Breast cancer; Malignant tumor; Metastasis; Mammary gland diseases; Alkaloid; Treatment; Taxane derivatives; Paclitaxel; Phase I trial; Advanced stage; Metastatic breast cancer; Antimitotic; Dose; Vinorelbine; Paclitaxel·Phase I
• ISSN: 0344-5704; 1432-0843
• DOI: 10.1007/s00280-006-0324-4

Intravenous (i.v.) vinorelbine (VRL) generally given on days 1 and 8 of an every three-week cycle in combination with paclitaxel (PTX) is an effective option for the treatment of metastatic breast cancer (MBC). In an effort to improve both patient and chemotherapy unit convenience, oral VRL was used at equivalent doses of i.v. VRL. The maximal tolerated dose (MTD) was determined during the first cycle of oral VRL given on days 1 and 8 or 15 and PTX infused over 3 h on day 1 every 3 weeks, maximum of 6 cycles. The dose of oral VRL was escalated from 60 to 80 mg/m2 in 10 mg/m2 increments. Paclitaxel was administered at 110 and then 135 mg/m2. The combination regimen was given as first-line chemotherapy of MBC. Three to six patients per cohort were treated. Twenty-two patients were treated in the first four cohorts (oral VRL/PTX): 60/110, 70/110, 80/110 and 80/135. In cohort 4, seven patients were treated, one patient being non-evaluable for MTD, three of them presented a dose-limiting toxicity (DLT) consisting of febrile neutropenia and neutropenic infection. Therefore 80/135 was the MTD. Because 36% of oral VRL administrations on day 8 were delayed to day 15 at 80/110, two additional cohorts were tested: in cohort 5, oral VRL 60 mg/m2 on days 1 and 15 and PTX 135 mg/m2 on day 1 and in cohort 6, oral VRL 80 mg/m2 on days 1 and 15 and PTX 110 mg/m2 on day 1, every 3 weeks. In cohort 5, six out of eight patients had DLTs: omission of oral VRL on day 15 for five patients, grade 4 neutropenia>7 days for another one. Therefore the recommended dose (RD) for further clinical testing was oral VRL 80 mg/m2 on days 1 and 15 and PTX 110 mg/m2 on day 1 of an every 3-week cycle. Two of the three evaluable patients treated at the RD had a partial response. The pharmacokinetics of VRL and PTX is being analysed and will be further presented in a separate publication. This phase I study has determined the doses of oral VRL and PTX to be used in combination for the benefit of the patient and of the chemotherapy unit in term of nurse's workload. The recommended regimen of oral VRL 80 mg/m2 on days 1 and 15 and PTX 110 mg/m2 on day 1 given every 3 weeks will be further tested in phase II.